In an era where practice in hepatology has been revolutionised by an avalanche of therapeutic breakthroughs, hepatocellular carcinoma (HCC) still stands as the most difficult to cure end-stage liver disease and the dominant cause of death of patients with compensated cirrhosis of any aetiology. In 2012, the death toll of HCC was impressive, resulting from 521,000 men and 224,500 women estimated to have died from liver cancer, meaning that this cancer was the second leading cause of cancer death in men and the sixth in women, worldwide.
To read the full article visit: The Journal of Hepatology
EASL releases Editorial response to Cochrane Review of DAAs in HCV
Journal of Hepatology cited over 30,000 times in 2016
Short duration of breastfeeding and maternal obesity linked to fatty liver in adolescents
Subscribe to the EASL newsletter